cholangiocarcinoma

(redirected from Bile duct tumor)
Also found in: Dictionary.

cholangiocarcinoma

 [ko-lan″je-o-kahr″sĭ-no´mah]
1. an adenocarcinoma arising from the epithelium of the intrahepatic bile ducts, composed of eosinophilic cuboidal or columnar epithelial cells, with abundant fibrous stroma; mucus may be secreted but not bile.

chol·an·gi·o·car·ci·no·ma

(kō-lan'jē-ō-kar'si-nō'mă),
An adenocarcinoma, primarily in intrahepatic bile ducts, composed of ducts lined by cuboidal or columnar cells that do not contain bile, with abundant fibrous stroma; cirrhosis is usually absent.

cholangiocarcinoma

A rare (5/105/year) cancer of intrahepatic bile ducts, seen > age 60.
 
Aetiology
Anabolic steroids, liver flukes (Clonorchis sinensis), ulcerative colitis, cholecystitis, cholelithiasis, primary sclerosing cholangitis, malformations, cirrhosis.

Clinical findings
Obstruction, jaundice, abdominal pain, weight loss.

Location
Hilar, 50–60%; intrahepatic, 10%; extrahepatic 20–30%.

Prognosis
53% 1-year survival; 4% 5-year survival.

cholangiocarcinoma

Bile duct cancer, cancer of bile ducts A rare–5/100,000/yr cancer of intrahepatic bile ducts seen > age 60 Etiology Anabolic steroids, Thorotrast,.Clonorchis sinensis, possibly ulcerative cholitis, cholecystitis; not associated with alcohol abuse Clinical Jaundice—71%, abdominal pain-49%, weight loss—44% Prognosis 53% 1-yr survival, 9% 3-yr, 4% 5-yr. Cf Hepatocellular carcinoma.

chol·an·gi·o·car·ci·no·ma

(kō-lan'jē-ō-kahr-si-nō'mă)
An adenocarcinoma, primarily in intrahepatic bile ducts, composed of ducts lined by cuboidal or columnar cells that do not contain bile, with abundant fibrous stroma.

cholangiocarcinoma

Cancer of the bile ducts.
References in periodicals archive ?
Imaging bile duct tumors: pathologic concepts, classification, and early tumor detection.
Intraductal papillary bile duct tumors may be identified in some patients with biliary obstruction and are classified as in situ tumors (Tis).
Exelixis' development pipeline currently covers cancer and metabolism and is comprised of the following compounds: XL119 (becatecarin), for which a Phase 3 clinical trial has been initiated in patients with bile duct tumors; XL784, initially an anticancer compound, which has completed a Phase 1 clinical trial and is currently being developed as a treatment for renal disease; XL647 and XL999, which are currently in Phase 1 clinical trials; XL880, XL820, XL844 and XL184, anticancer compounds that are potential IND candidates; and multiple compounds in preclinical development for diseases including cancer, lipid disorders, hyperlipidemia and congestive heart failure.
Carcinomas arising in the middle portion of the extrahepatic bile duct are classified according to their treatment (combined hepatic and hilar resection for perihilar tumors, pancreaticoduodenectomy for distal bile duct tumors).
Data presented at the 2003 annual meeting of the American Society of Clinical Oncology (ASCO) from the Phase 2 clinical trial of XL119 showed that patients with bile duct tumors (gall bladder tumors and cholangiocarcinomas) treated with XL119 showed encouraging results relative to overall survival and progression free survival (alive without progressive disease, i.e., patients with partial response or stable disease).